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Abstract
Introduction The impact of interactions between the two
estrogen receptor (ER) subtypes, ERα and ERβ, on gene
expression in breast cancer biology is not clear. The goal of this
study was to examine transcriptomic alterations in cancer cells
co-expressing both receptors and the association of gene
expression signatures with disease outcome.
Methods Transcriptional effects of ERβ overexpression were
determined in a stably transfected cell line derived from ERα-
positive T-47D cells. Microarray analysis was carried out to
identify differential gene expression in the cell line, and
expression of key genes was validated by quantitative
polymerase chain reaction. Microarray and clinical data from
patient samples were then assessed to determine the in vivo
relevance of the expression profiles observed in the cell line.
Results A subset of 14 DNA replication and cell cycle-related
genes was found to be specifically downregulated by ERβ.
Expression profiles of four genes, CDC2, CDC6, CKS2, and
DNA2L, were significantly inversely correlated with ERβ
transcript levels in patient samples, consistent with in vitro
observations. Kaplan-Meier analysis revealed better disease
outcome for the patient group with an expression signature
linked to higher ERβ expression as compared to the lower ERβ-
expressing group for both disease-free survival (p = 0.00165)
and disease-specific survival (p = 0.0268). These findings were
further validated in an independent cohort.
Conclusion Our findings revealed a transcriptionally regulated
mechanism for the previously described growth inhibitory
effects of ERβ in ERα-positive breast tumor cells and provide
evidence for a functional and beneficial impact of ERβ in primary
breast tumors.
Introduction
Estrogens are involved in a number of vertebrate developmen-
tal and physiological processes and have been implicated in
certain types of endocrine-related tumors [1-4]. Hormone
response in target tissues is mediated by nuclear receptors
that function as ligand-dependent transcription factors.
Receptor function is further modulated by post-translational
modifications and interactions with other nuclear proteins.
Originally, only one type of estrogen receptor (ER) was
thought to be involved in hormone signaling. However, a sec-
ond ER, termed ERβ, was subsequently discovered, adding
another dimension of complexity to the regulation of hormone
response. The original receptor was renamed ERα [5].
CDC2 = cell division cycle 2; CDC6 = cell division cycle 6; CKS2 = cell division cycle 28 protein kinase regulatory subunit 2; DNA2L = DNA repli-
cation helicase 2-like; Cy = cyanine; DBD = DNA-binding domain; DCCFBS = dextran-coated charcoal-treated fetal bovine serum; DFS = disease-
free survival; DMEM = Dulbecco's modified Eagle's medium; DSS = disease-specific survival; ER = estrogen receptor; ERE = estrogen response 
element; FBS = fetal bovine serum; PCR = polymerase chain reaction; TET = tetracycline.Breast Cancer Research    Vol 9 No 2    Lin et al.
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ERα and ERβ show 55% identity in their ligand-binding
domains and approximately 97% similarity in the DNA-binding
domains (DBDs). Both ERs bind estradiol with high affinity but
vary in their ability to bind other natural and synthetic ligands
and the types of response elicited upon ligand binding [6-8].
Reflecting the high degree of similarity in their DBDs, both
receptors interact with the same conserved estrogen
response element (ERE) (5'-GGTCAnnnTGACC-3') as either
homodimers or α/β heterodimers [9-11]. Tissue-specific
expression and co-expression of receptor subtypes suggest
that ER homodimers and heterodimers may mediate distinct
hormone responses [12-15]. Moreover, the discovery of ERβ
variants with different structural and functional characteristics
and tissue distribution further highlighted the potential com-
plexity of the interactions between ERs and the mechanisms
by which estrogen response is modulated [16-20].
The predominant impact of ER activation appears to be alter-
ations in the transcriptional activity and expression profiles of
target genes. A number of genes, including trefoil factor 1/
pS2, cathepsin D, cyclin D1, c-Myc, and the progesterone
receptor, are positively regulated by estrogen treatment [21].
Transcriptional repression by ER has not been as well studied.
However, by means of SAGE (Serial Analysis of Gene Expres-
sion) and DNA microarrays, many more estrogen-responsive
genes, induced or repressed by the hormone, have been iden-
tified and characterized [22-29]. Much of the work on gene
expression has been focused on the role of ERα, but little is
known about genes specifically targeted by ERβ or by α/β het-
erodimers. Recent microarray experiments using knockout ani-
mals indicate that target tissues in ERβ knockouts exhibited an
overall increased transcriptional response to hormone treat-
ment as compared to wild-type controls [30]. Expression stud-
ies of osteosarcoma cells stably transfected with each
receptor subtype suggest that ERα and ERβ share some com-
mon target genes, although each receptor also appears to
have distinct sets of downstream targets [31]. Despite these
efforts, the exact transcriptional effects of ERα and ERβ in
breast cancer remain obscure.
To characterize the impact of ERβ expression on hormone
response in ERα-positive breast tumor cells, we have stably
transfected T-47D (ERα+/ERβ-) cells with an inducible ERβ
expression construct to generate subline T-47Dbeta. Induc-
tion of ERβ expression in this cell line was shown to inhibit
estrogen-responsive cell proliferation [32]. These observa-
tions are consistent with other reports that describe the
growth-inhibitory effects of ERβ [33,34]. Using high-density
DNA microarrays under conditions that induce ERβ expres-
sion and following hormone treatment, we screened for poten-
tial transcriptional effects of the ERαβ co-expression. Here, we
present a set of cell cycle and DNA replication genes respon-
sive to ERβ expression and estrogen treatment and their
potential roles in the biology of primary breast tumors.
Materials and methods
Cell culture
T-47D cells were cultured in a mixture of Dulbecco's modified
Eagle's medium (DMEM) and Ham's F-12 1:1 supplemented
with 5% fetal bovine serum (FBS), penicillin, and streptomycin.
For experiments using 17β-estradiol, DMEM without phenol
red and FBS treated with dextran-coated charcoal were used.
Transfection and plasmids
T-47D cells stably transfected with tetracycline (TET)-regu-
lated ERβ expression plasmid were generated in two steps: (a)
The cells were first transfected with pTet-tTAk (Invitrogen Cor-
poration, Carlsbad, CA, USA) modified to contain puromycin
resistance using lipofectin according to manufacturer's
instructions (Invitrogen Corporation). Selection was per-
formed with 0.5 μg/ml of puromycin in the presence of 1 μg/
ml of TET. A good clone showing a high level of induction and
low basal activity was selected using the pUHC13-3 control
plasmid (Invitrogen Corporation). The short form of ERβ
encoding 485 amino acids was fused to the flag tag (ERβ485)
and cloned into PBI-EGFP (Clontech, Mountain View, CA,
USA). (b) This construct was then transfected into the previ-
ously described inducible clone together with a neomycin-
resistance plasmid. The selection was performed using 500
μg/ml of G418 (Calbiochem, brand of EMD Biosciences, Inc.,
San Diego, CA, USA).
Preparation of RNA
Cells were added to 150-mm plates at a confluency of 40%;
after 1 day, the normal medium was replaced by the medium
described above, supplemented with 5% dextran-coated
charcoal-treated FBS (DCCFBS). After 24 hours, 10 nM ICI
182780 (fulvestrant) was added to the cultures and incuba-
tion proceeded for an additional 48 hours. For expression of
ERβ, TET was removed 12 hours before initiation of treatment
with 17β-estradiol. At time 0 hours, the medium was changed
to 0.5% DCCFBS and 10 nM of 17β-estradiol or the equiva-
lent volume of dimethyl sulfoxide for mock-treated controls
was added. RNA was prepared by adding 10 ml of Trizol (Inv-
itrogen Corporation) to each 150-mm plate at different time
points after the start of treatment, and RNA was prepared
according to the manufacturer's instructions.
Microarray analysis
Microarrays were generated by spotting the Compugen USA,
Inc. (Jamesburg, NJ, USA) 19 K human oligo library, made by
Sigma-Genosys (The Woodlands, TX, USA), on poly-L-lysine-
coated glass slides. Twenty-five micrograms each of sample
total RNA and human universal reference RNA (Stratagene, La
Jolla, CA, USA) were labeled with cyanine (Cy) 5-conjugated
dUTP and Cy3-conjugated dUTP (PerkinElmer Life and Ana-
lytical Sciences, Inc., Waltham, MA, USA), respectively, and
hybridized to the arrays using protocols established by the
Patrick O. Brown Laboratory (Stanford University, Palo Alto,
CA, USA) accessible at [35]. Array images and data wereAvailable online http://breast-cancer-research.com/content/9/2/R25
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obtained and processed using the GenePix4000B scanner
and GenePix Pro software (Axon Instruments, Inc., now part of
Molecular Devices Corporation, Sunnyvale, CA, USA). A sin-
gle sample from each time point and treatment condition was
subjected to microarray analysis. Differentially expressed
genes were determined using a 1.15-fold difference cutoff at
multiple time points and were clustered and visualized using
the Eisen Cluster and TreeView programs [36]. Gene ontology
of responsive genes was derived from annotations (2002 ver-
sion) made by Compugen USA, Inc. Significant enrichment of
functional categories was determined by chi statistics by com-
paring the distribution of genes in a given functional category
for all of the genes represented on the microarray (expected
distribution) with the distribution of genes in the same func-
tional category in differentially expressed genes (observed dis-
tribution). The p value was then calculated based on a two-
tailed chi distribution, and a p value of less than 0.05 was con-
sidered a significant difference between the observed and
expected values. The data are presented as the log2-trans-
formed ratio between the treated/induced samples and the
mock treated-uninduced controls for the same time point. The
cell line microarray data have been deposited with the Gene
Expression Omnibus under accession number GSE7206, and
the normalized log2-transformed fold-change data are pre-
sented in Additional file 1.
Real-time relative quantification polymerase chain 
reaction
For validation of microarray data, RNA samples from the 30-
hour time point were converted to cDNA by means of the Pow-
erScript (Clontech) reverse transcriptase in accordance with
the recommended protocol with 1 μg of total RNA. Quantifica-
tion of transcript levels was performed using SYBR Green
chemistry on the ABI PRISM® 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). Polymer-
ase chain reaction (PCR) amplification was carried out in 20
μl of reaction mixture consisting of 50 nM of primer pairs. The
following primers were used for PCRs: cell division cycle 2
(CDC2), CCCAAATGGAAACCAGGAAG (forward), CGTTT-
GGCTGGATCATAGAT (reverse); cell division cycle 6
(CDC6), GGAAACCCGTTTGACAAAGG (forward),
CGGGTGGGGTGTAAGAGAAGAATT (reverse); cell divi-
sion cycle 28 protein kinase regulatory subunit 2 (CKS2),
CTGATGTCTGAAGAGGAGTG  (forward), GGAAGAG-
GTCGTCTAAAGAG (reverse); DNA replication helicase 2-
like (DNA2L), GGATGGAACTGTTGGTGAAC (forward),
ATTTAGTGAGGGCACACACC (reverse); ERβ, TCCAT-
GCGCCTGGCTAAC (forward), CAGATGTTCCAT-
GCCCTTGTTA (reverse); and β actin,
ACCCACACTGTGCCCATCTACGAG (forward), TCTCCT-
TAATGTCACGCACGATTTCC (reverse). 18S rRNA Pre-
developed TaqMan®  Assays by Applied Biosystems were
used as reference gene.
Patients and tumor specimens
The original patient material consisted of freshly frozen breast
tumors that came from a population-based cohort of 315
women and that represented 65% of all breast tumors
resected in Uppsala County, Sweden, from 1 January 1987 to
31 December 1989 [37,38]. The follow-up RNA expression
profiling study was approved by the ethical committee at the
Karolinska Institute, Stockholm, Sweden. Affymetrix (Santa
Clara, CA, USA) oligonucleotide microarrays (U133A&B)
were used to determine gene expression profiles in breast
tumor samples. After exclusions based on RNA integrity and
array quality control, expression profiles of 260 tumors were
deemed suitable for further analysis [37]. To assess the role of
ERβ-regulated cell cycle and DNA replication genes in breast
tumor biology, we selected the 69 ER-positive tumors from
patients who underwent adjuvant tamoxifen therapy (see Addi-
tional file 2). Clinico-pathological characteristics were derived
from the patient records and from routine clinical measure-
ments at the time of diagnosis as described elsewhere [37].
Histopathological re-examination and grading according to
Elston-Ellis were performed by an experienced breast cancer
pathologist without prior knowledge of selected therapies and
outcomes. Gene expression data are presented as mean-cen-
tered log2-transformed normalized intensity for the probe set.
The distances between expression profiles were calculated
based on Pearson correlation, and the average-linkage
method from the Eisen Cluster program was used to cluster
genes and tumor samples. All cluster data were generated in
the same way and using the same parameters to maintain the
consistency of the analysis.
Results
Screen for ERβ-regulated E2-responsive genes
ERβ expression was induced in the T-47Dbeta subline by TET
withdrawal (see Materials and methods), and global gene
expression profiles in the presence or absence of hormone
were determined by human oligonucleotide microarrays
(approximately 19,000 genes; Compugen USA, Inc.) at 1, 6,
12, 16, and 30 hours following induction. The preliminary
expression data were subjected to a filter for genes that exhib-
ited at least a 1.15-fold differential expression ratio between
induced and treated samples and mock-treated (-E2)-unin-
duced (+TET) controls at each time point and in the same
direction for three consecutive time points or in four out of the
five time points. Eight hundred ninety-three upregulated genes
and 728 downregulated genes met the selection criteria.
These parameters were selected based on previously pub-
lished time-course data and the ability to capture known
responsive genes [28]. We then examined the expression pro-
files of responsive genes by hierarchical clustering. Two clus-
ters of genes emerged which may explain the antagonistic
activity of ERβ on cell growth. The first cluster contains genes
whose expression levels were upregulated by E2 treatment
but downregulated following ERβ expression alone or E2
treatment and ERβ expression (Figure 1a). Among the genesBreast Cancer Research    Vol 9 No 2    Lin et al.
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found within this cluster, PCNA (proliferating cell nuclear anti-
gen) and CDC6 are both known to be involved in DNA repli-
cation and have been shown to be estrogen-responsive genes
[29,39]. The second cluster includes CDC2 and CKS2, two
cell cycle regulatory genes that were also downregulated by
ERβ expression in the presence and absence of E2 (Figure
1b). The highly specific contrary regulation of a small number
of genes, specifically the downregulation of genes involved in
cell cycle regulation and DNA replication, presents a plausible
mechanism by which ERβ or α/β heterodimers can block E2-
induced cell proliferation.
ERβ disrupts expression of cell cycle and DNA replication 
genes
To determine whether specific molecular pathways and proc-
esses are affected by ERβ expression, we assessed in an
unbiased fashion whether the genes that were perturbed
could be assigned to functional categories by gene ontology
and whether genes of a specific function in cell proliferation
were statistically significantly enriched, as measured by χ2
tests, when compared to the frequency of these genes repre-
sented on the microarray (gene ontology annotated by Com-
pugen USA, Inc.; see Additional File 3) (Table 1).
We first observed that ERβ in the presence of E2 did not sig-
nificantly upregulate any specific functional class of genes.
However, in the downregulated genes, we observed 1.7-fold
(2.6% versus 1.5%) enrichment in the frequency of cell cycle
genes (χ2 p = 0.0241) and a 2.8-fold (1.4% versus 0.5%)
enrichment in DNA replication genes (χ2 p = 0.00175). We
then further divided the 728 downregulated genes into expres-
sion profiles relative to E2 treatment alone into three models of
interactions between ERβ and ERα. In the synergistic model,
ERβ overexpression enhances E2 response, whereas in the
attenuation model, ERβ diminishes the observed E2-regulated
gene expression. When genes exhibit opposite E2-responsive
regulation following ERβ expression, they are categorized
under the antagonistic model of interaction between ERβ and
ERα. All genes were assigned to these categories based on a
cutoff of greater than (synergistic) or less than (attenuation)
the E2 response or if the fold-change had an opposite (+ or -)
notation (antagonistic) after log2 transformation. Table 2
shows the enrichment of responsive genes in the four cell pro-
liferation/growth-associated functional categories. We found
that cell cycle genes were over-represented (5.6-fold; χ2 p =
0.00077) in the group described by the antagonistic model
and that DNA replication genes were enriched 3.2-fold (χ2 p =
0.0008) in the group that showed attenuation by ERβ of the
E2-mediated transcriptional induction. Thus, it appears that
ERβ can specifically regulate the proliferative effects of E2 and
ERα by reducing the expression levels of components of the
cell cycle and DNA replication machinery.
Gene expression profiles in patient samples
We sought to address whether this in vitro effect of ERβ on
proliferation could explain some of the heterogeneity in biolog-
ical behavior of ERα-positive breast cancer. We posited that
higher ERβ levels would be correlated with lower expression
of these specific DNA replication and cell cycle genes and, in
turn, would be associated with better clinical outcome. To test
this hypothesis, we examined ERβ transcript levels in primary
breast tumors with the expression profiles of ERβ-regulated
cell cycle genes identified in our in vitro analysis and their
association with clinical outcome.
To study these in vitro observations in a biologically and clini-
cally relevant context in which ERα is present and the function
Figure 1
Two clusters of genes showing disruption of estrogen-responsive  expression profiles by estrogen receptor beta (ERβ) overexpression Two clusters of genes showing disruption of estrogen-responsive 
expression profiles by estrogen receptor beta (ERβ) overexpression. 
(a) The columns represent time points arranged in chronological order, 
and each row represents the expression profile of a particular gene. By 
convention, upregulated genes are indicated by red signals and down-
regulated genes are indicated by green. The magnitude of change is 
proportional to the brightness of the signal. (b) Second cluster of genes 
disrupted by ERβ overexpression.Available online http://breast-cancer-research.com/content/9/2/R25
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of estrogen-responsive pathways was targeted by anti-estro-
gen treatment, we specifically examined microarray expression
d a t a  f r o m  6 9  E R α-positive breast tumors from patients
belonging to a previously described cohort [37,38] from Upp-
sala, who had received adjuvant tamoxifen therapy following
surgery (see Materials and methods). We extracted the
expression data of the six cell cycle and eight DNA replication
genes (Table 2) that were downregulated by ERβ in the pres-
ence of E2 and classified the tumors based on their expression
profiles. Two of the eight DNA replication genes were not
found on the arrays used for the tumor studies, so only 12
genes in total were available for analysis. We first assessed
whether ERβ expression was associated with a decrease in
the expression of the ERβ-regulated cell cycle genes. When
we examined these genes, we found that for the majority of
them (10/12; 83%), there is negative correlation between ERβ
transcript levels and the ERβ-responsive genes (Table 3). This
is consistent with our in vitro findings that overexpression of
ERβ leads to the downregulation of these genes. Four genes,
CDC2, DNA2L, CDC6, and CKS2, were significantly (Stu-
dent t test p < 0.05) associated with ERβ transcript levels in
the microarray data. The estrogen-dependent upregulation of
these genes and the suppression of their expression by ERβ
overexpression in the cell line were further validated by semi-
quantitative PCR (Figure 2) in cells treated for 30 hours with
E2 to replicate prolonged estrogen exposure of breast tumor
cells in vivo.
We then focused our analysis on these four validated ERβ-reg-
ulated genes (CDC2, CKS2, CDC6, and DNA2L) with signif-
icant correlation with ERβ expression in the tumors as the
functional ERβ-responsive gene set for subsequent clustering
and associations with clinical parameters (Figure 3). With the
expression of the ERβ-responsive gene set, tumor samples
were clustered (average linkage) into two major groups with
statistically significant association with 10-year relapse (Fisher
exact p = 0.0015), death (Fisher exact p = 0.0401), and tumor
grade (Fisher exact p = 0.0128) as compared to the distribu-
tion of the parameters tested in the study population.
Using disease-free survival (DFS) (Figure 3b) and disease-
specific survival (DSS) (Figure 3c) as clinical endpoints, we
performed Kaplan-Meier survival analysis on the two patient
clusters to ascertain the correlation between the molecular
signature and disease outcome. Patients with relatively higher
levels of ERβ and lower expression of the gene set transcript
(Figure 3a, cluster 1; Figure 3b,c, black curves) have signifi-
cantly improved outcomes compared to the group with lower
levels of ERβ and higher responsive gene set transcript levels
(Figure 3a, cluster 2; Figure 3b,c, red curves) for both end-
points, DFS (likelihood-ratio p = 0.0017) and DSS (likelihood-
ratio p = 0.0268). As expected, we did not observe any signif-
icant association of the ERβ-responsive gene set expression
profiles with disease outcome in 37 ERα-negative tumors from
the same patient population (data not shown). These results
were further validated in an independent dataset of 45 ERα-
positive tumors from patients who also underwent endocrine
Table 1
Statistics of key gene ontology categories
Gene function Percentage total χ2 p value
E2 + ERβ upregulated
Apoptosis 1.1% (10/893) 0.18590
Cell cycle 1.5% (13/893) 0.82478
Cell proliferation 0.4% (4/893) 0.41984
DNA replication 0.4% (4/893) 0.80576
E2 + ERβ downregulated
Apoptosis 0.4% (3/728) 0.31923
Cell cycle 2.6% (19/728) 0.02471
Cell proliferation 0.3% (2/728) 0.91690
DNA replication 1.4% (10/728) 0.00175
All genes on array
Apoptosis 0.7% (138/18,912) -
Cell cycle 1.5% (293/18,912) -
Cell proliferation 0.3% (56/18,912) -
DNA replication 0.5% (96/18,912) -
ERβ, estrogen receptor beta.Breast Cancer Research    Vol 9 No 2    Lin et al.
Page 6 of 11
(page number not for citation purposes)
therapy [40]. In this independent dataset of British patients,
the ERβ-responsive gene set expression profiles also identi-
fied patients in high and low ERβ gene set expression groups
(Figure 4a) and to poor and good outcome groups for DFS
(Figure 4b, likelihood-ratio p = 0.0162) and DSS (Figure 4c,
likelihood-ratio p = 0.0192), respectively. Our findings indi-
cate that the observed in vitro activity of ERβ on downstream
target genes is directly recapitulated in primary breast tumors
and has utility in further demarcating prognostic and therapeu-
tic subgroups in the clinical setting. In addition, these results
implicate the selective ERβ transcriptional effects as identified
in vitro in defining clinical behavior of human breast tumors.
Discussion
Original characterization of ERβ function indicated its ability to
form homodimers and heterodimers (with ERα) and to bind the
same consensus ERE sequences in electrophoretic mobility
shift experiments [9]. However, the biological effects of ERβ
are considerably different from those of ERα: ERβ expression
alone, unlike hormone treatment, was not sufficient to drive cell
proliferation [28]. In cell lines, overexpression of ERβ inhibited
E2-driven and ERα-mediated cell proliferation [28]. In our
microarray screen for transcriptional effects of ERβ expression
in ERα-positive cells, statistical analysis indicated a significant
enrichment of genes from two cell growth-associated func-
tional categories within the population of genes downregu-
lated by ERβ in the presence of E2 (Tables 2 and 3). However,
because both receptor subtypes are present in the cells, it is
not clear from the experimental system whether the observed
transcriptional effects were due to the activity of ERβ
homodimers or α/β heterodimers.
One of the difficulties in assessing the biological significance
of such associations between in vitro gene expression
changes and the cellular response is that a number of genes
coordinately expressed (for example, the ERβ-responsive
gene set) may be involved. One-by-one targeting of all respon-
sive genes not only is experimentally problematic but also
raises the question of relevance given that an entire gene set
may need to be altered. We pursued an alternative approach
to determining the in vivo relevance of these findings in the
engineered cell line by exploring the association of ERβ tran-
script levels and the key ERβ-suppressed cell cycle and DNA
replication genes in disease outcome of patients with breast
cancer. We hypothesized that if our in vitro findings were bio-
logically important, their configuration should be captured in
Table 2
Statistics of key gene ontology categories by mechanism of regulation in 728 E2 + ERβ downregulated genes
Gene function Percentage total χ2 p value
'Synergistic'
Apoptosis 0% (0/129) 0.33018
Cell cycle 0.8% (1/129) 0.47730
Cell proliferation 0% (0/129) 0.53595
DNA replication 0.8% (1/129) 0.67051
'Attenuation'
Apoptosis 0.4% (2/492) 0.40303
Cell cycle 1.8% (9/492) 0.11725
Cell proliferation 0.2% (1/492) 0.70713
DNA replication 1.6% (8/492) 0.00080
'Antagonistic'
Apoptosis 0.9% (1/107) 0.80404
Cell cycle 8.4% (6/107) 0.00077
Cell proliferation 0.9% (1/107) 0.22828
DNA replication 0.9% (1/107) 0.53640
All genes on array
Apoptosis 0.7% (138/18,912) -
Cell cycle 1.5% (293/18,912) -
Cell proliferation 0.3% (56/18,912) -
DNA replication 0.5% (96/18,912) -
ERβ, estrogen receptor beta.Available online http://breast-cancer-research.com/content/9/2/R25
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clinical tumors and their biological impact should recapitulate
that found in cell culture.
To this end, we first found significant association of the expres-
sion profiles of four genes, CDC2,  CKS2,  DNA2L, and
CDC6, with ERβ transcript levels in the breast tumors, con-
sistent with the inverse correlation (high ERβ; low cell cycle/
DNA replication genes) observed in the cell line model. CDC2
is a cyclin-dependent kinase that regulates G1-S and G2-M
phases of the cell cycle; CKS2 encodes the essential regula-
tory subunit of cyclin-dependent kinases; and CDC6  and
DNA2L function in the pre-replication complex formation and
unwinding of replicating DNA, respectively. Tumor samples
were then hierarchically clustered into two distinct groups,
using the expression profiles of this four-gene set and ERβ
(Figure 3). We found significant association of the patient
groups with tumor grade (which we consider a clinical surro-
gate for cell cycle and DNA replication) and with 10-year
relapse and death. Moreover, the patient cluster with high ERβ
and low ERβ downstream gene expression has significantly
higher probability of DFS and DSS over time as compared to
those with the opposite profiles. These results suggest that
the ERβ-regulated genes identified in our in vitro studies are
also involved in the biology of primary malignant breast tumors
and reveal protective effects of ERβ in disease prognosis. That
this effect is limited to the ERα-positive subgroup is also con-
sistent with our observations that the main ERβ effect is in the
presence of ERα and the E2 ligand. Previously, we reported
that ER-positive tumors exhibited significant differences
detected by expression profiling associated with variances in
overall survival [40]. Using the same dataset, we assessed the
impact of ERβ and its unique downstream responsive gene set
and found that this minimal gene set alone could account for
the majority of the survival differences [40]. This suggests that
ERβ status may be a major driver for clinical heterogeneity in
ER-positive tumors.
Our findings are consistent with a recent report by Hopp and
colleagues [41] in which they found that low ERβ protein lev-
els are associated with poor DFS and overall survival in ER-
positive patients treated with adjuvant tamoxifen therapy. In
contrast, another group reported the lack of association
between ERβ transcript levels and disease outcome following
endocrine therapy in a prospective study [42]. One possible
explanation for the discrepancy between the prospective
study and the previous protein level study and the microarray
expression data reported here is that protein levels and
expression profiles of downstream ERβ-regulated genes are a
more proximal measure of ERβ activity than the transcript lev-
els alone.
A reasonable question is whether the ERβ downstream genes
harbor the transcriptional control elements associated with the
ERs (that is, EREs). Our assessment of the 5' regulatory
regions of the four key downstream genes CDC2,  CKS2,
DNA2L, and CDC6 showed no evidence for an acceptable
ERE (data not shown). This raises the possibility either that the
expression of these genes involves trans-elements such as
other transcription factors induced by ERβ or that ERβ is act-
ing as a co-factor for other transcription factors such as AP-1
[43,44]. In an earlier microarray study of estrogen-responsive
genes, Lobenhofer and colleagues [39] observed an increase
Table 3
Association with estrogen receptor beta expression in 69 breast tumors
UniGene IDa Symbol Correlation p value
Hs.334562 CDC2 -0.30798 0.00151
Hs.194665 DNA2L -0.22919 0.01522
Hs.405958 CDC6 -0.16138 0.02774
Hs.83758 CKS2 -0.21564 0.04152
Hs.156346 TOP2A -0.11536 0.07061
Hs.436806 RAMP -0.20123 0.07442
Hs.436102 FLJ12484 0.05731 0.08202
Hs.115474 RFC3 -0.19135 0.11683
Hs.139226 RFC2 -0.09613 0.12292
Hs.135665 GAS2 0.05865 0.24376
Hs.142179 INCENP -0.03967 0.29616
Hs.234896 GMNN -0.07458 0.36950
Hs.22116 CDC14Bb N/A N/A
N/A PRO0245b N/A N/A
aUniGene Build 175; bnot found on the arrays. N/A, not applicable.Breast Cancer Research    Vol 9 No 2    Lin et al.
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Figure 2
Validation of estrogen-responsive regulation of cell cycle and DNA replication genes suppressed by estrogen receptor beta (ERβ) overexpression by  real-time quantitative polymerase chain reaction Validation of estrogen-responsive regulation of cell cycle and DNA replication genes suppressed by estrogen receptor beta (ERβ) overexpression by 
real-time quantitative polymerase chain reaction. CDC2, CDC6, DNA2L, and CKS2 were selected for further validation based on their significant 
correlation with ERβ transcript levels, and β actin expression was assessed as a negative control. Transcript levels in T-47Dbeta cells were meas-
ured at 30 hours following estrogen treatment (+E2) or mock treatment and under induction (-TET [+ERβ]) and non-induction (+TET) conditions. 
Relative fold-changes were calculated using the non-induced (+TET) samples as the reference. CDC2, cell division cycle 2; CDC6, cell division 
cycle 6; CKS2, cell division cycle 28 protein kinase regulatory subunit 2; DNA2L, DNA replication helicase 2-like; TET, tetracycline.
Figure 3
Clustering of 69 tumor samples by ERβ/ESR2, CDC2, CDC6, DNA2L, and CKS2 expression profiles is associated with clinical parameters and dis- ease outcome Clustering of 69 tumor samples by ERβ/ESR2, CDC2, CDC6, DNA2L, and CKS2 expression profiles is associated with clinical parameters and dis-
ease outcome. (a) Hierarchical clustering of tumor samples into two groups of high (black dendrogram; cluster 1) and low (red dendrogram; cluster 
2) expression clusters. Clinical parameters, including relapse and death from breast cancer within 10 years of surgery and lymph node-positive 
(LN+) status, are indicated with a solid bar beneath each tumor sample. Tumor grade is indicated by colored bars; green, blue, and red bars denote 
grades 1, 2, and 3, respectively. Gray bars denote missing data. Significant distribution of clinical parameters between the two clusters was deter-
mined by Fisher exact tests, and p values were derived from the calculated distributions. (b) Kaplan-Meier plot of 10-year censored disease-free sur-
vival (DFS) curves for cluster 1 (black) and cluster 2 (red) patients is shown with the associated p values from likelihood-ratio analysis. (c) Kaplan-
Meier plot of 10-year censored disease-specific survival (DSS) curves for cluster 1 (black) and cluster 2 (red) patients is shown with the associated 
p values from likelihood-ratio analysis. CDC2, cell division cycle 2; CDC6, cell division cycle 6; CKS2, cell division cycle 28 protein kinase regulatory 
subunit 2; DNA2L, DNA replication helicase 2-like; ERβ/ESR2, estrogen receptor beta.Available online http://breast-cancer-research.com/content/9/2/R25
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in the expression of a number of DNA replication fork genes,
including those that have been shown to be regulated by the
E2F transcription factor. Indeed, a number of studies showed
that E2F is involved in regulating the expression of CDC6 [45-
47]. These findings suggest that ERβ may affect cell prolifera-
tion, in part, through interactions with the E2F transcriptional
regulatory pathways.
Conclusion
Taken together, our observations point to specific inhibitory
effects of ERβ on hormone-dependent breast cancer cell pro-
liferation and also suggest that molecules directly targeting
ERα/ERβ interactions or ERβ mimics could be a novel strategy
to develop estrogen response modifiers for the management
of ERα-positive breast tumors.
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